Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villeurbanne – page 150

2 127 clinical trials in Villeurbanne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villeurbanne at a glance
2 127
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 127 trials in Villeurbanne

Open in trial search

Ovarian cancer

Not recruiting

Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study on MAS825 for Patients with Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Arumakimig
  • Sponsor:Novartis Pharma AG

Myxoid liposarcoma+2

Not recruiting

Study of Afamitresgene Autoleucel for Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Afamitresgene Autoleucel
  • Sponsor:USWM Ct LLC

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lorlatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Villeurbanne

What the registry says about research in the country

01 Neurodegenerative Diseases

Extensive research focusing on Alzheimer's disease treatments, including multiple studies evaluating novel therapeutic approaches for early-stage patients. Additional investigations examine Parkinson's disease and serotonergic receptor expression.

  • Early Alzheimer's Disease Interventions
  • Parkinson's Disease Mechanisms
  • Cognitive Function Assessment

Studies utilize innovative compounds and treatment strategies to address disease progression and symptoms.

02 Cardiovascular Health

Innovative research targeting heart failure prevention through combination therapy approaches. Studies evaluate new treatment strategies for reducing cardiovascular risks and improving patient outcomes.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Combined Therapeutic Approaches

Focus on preventive strategies and risk reduction in high-risk populations.

03 Oncology Research

Comprehensive studies in various cancer types, including colorectal cancer, breast cancer, and gastric cancer. Research emphasizes personalized treatment approaches and innovative therapeutic strategies.

  • Colorectal Cancer Treatment
  • Breast Cancer Hormone Therapy
  • Gastrointestinal Oncology

Trials incorporate advanced diagnostic methods and targeted therapies.

04 Respiratory Medicine

Studies examining treatments for severe asthma and COPD, evaluating new therapeutic combinations and investigating treatment responses in respiratory conditions.

  • Asthma Management
  • COPD Interventions
  • Respiratory Treatment Optimization

Focus on improving pulmonary outcomes and patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.